Skip to main content

Table 5 Risk of bias included in SRs/MAs by ROBIS

From: The role of Shenqi Fuzheng injection as adjuvant therapy for breast cancer: an overview of systematic reviews and meta-analyses

Phase

Production process

Yang AL 2018 [29]

Wu JH 2019 [8]

Liu SY 2018 [6]

Lv YH 2015 [30]

Li Y 2016 [31]

Zhang HB 2019 [7]

Phase1

Study eligibility criteria

Low Risk

Low Risk

Low Risk

Low Risk

Low Risk

Low Risk

Phase 2

â‘ Identification and selection of studies

Low Risk

Low Risk

Low Risk

Low Risk

Low Risk

Low Risk

â‘¡Data collection and study appraisal

HIgh Risk

HIgh Risk

Low Risk

unclear risk

Low Risk

Low Risk

â‘¢Data extraction and quality evaluation

HIgh Risk

HIgh Risk

Low Risk

Low Risk

Low Risk

Low Risk

â‘£Data synthesis and result presentation

HIgh Risk

Low Risk

Low Risk

HIgh Risk

Low Risk

Low Risk

Phase 3

Risk of bias in the review

HIgh Risk

Low Risk

Low Risk

HIgh Risk

HIgh Risk

Low Risk